

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM585553

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	Amendment No. 1 to Trademark Security Agreement		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Sarepta Therapeutics, Inc.		07/02/2020	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	BIOPHARMA CREDIT PLC		
<b>Street Address:</b>	C/O BEAUFORT HOUSE, 51 NEW NORTH ROAD		
<b>City:</b>	EXETER EX4 4EP		
<b>State/Country:</b>	UNITED KINGDOM		
<b>Entity Type:</b>	Public Limited Company: ENGLAND AND WALES		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	6059005	EXONDYS 51 ETEPLIRSEN INJECTION	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2028874288		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2149692741		
<b>Email:</b>	blove@akingump.com		
<b>Correspondent Name:</b>	AKIN GUMP STRAUSS HAUER & FELD LLP		
<b>Address Line 1:</b>	2001 K Street NW		
<b>Address Line 4:</b>	Washington, D.C. 20006		
<b>ATTORNEY DOCKET NUMBER:</b>	687747.0035		
<b>NAME OF SUBMITTER:</b>	Brenda Love		
<b>SIGNATURE:</b>	/Brenda Love/		
<b>DATE SIGNED:</b>	07/09/2020		
<b>Total Attachments: 4</b>			
source=Pharmakon -- Sarepta - Amendment No. 1 to Trademark Security Agreement 4835-1630-3298, 1#page1.tif			
source=Pharmakon -- Sarepta - Amendment No. 1 to Trademark Security Agreement 4835-1630-3298, 1#page2.tif			
source=Pharmakon -- Sarepta - Amendment No. 1 to Trademark Security Agreement 4835-1630-3298, 1#page3.tif			
source=Pharmakon -- Sarepta - Amendment No. 1 to Trademark Security Agreement 4835-1630-3298, 1#page4.tif			

CH \$40.00 6059005

## AMENDMENT NO. 1 TO TRADEMARK SECURITY AGREEMENT

THIS AMENDMENT NO. 1 TO TRADEMARK SECURITY AGREEMENT (this "Amendment"), dated as of July 2, 2020 (the "Effective Date"), is made by SAREPTA THERAPEUTICS, INC. ("Grantor" or "Borrower"), in favor of BIOPHARMA CREDIT PLC (together with its successors and permitted assigns, the "Collateral Agent") on behalf of Lenders and the other Secured Parties (as defined in the Loan Agreement referred to below).

### WITNESSETH:

WHEREAS, pursuant to the Loan Agreement, dated as of December 13, 2019 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), by and among Grantor, BIOPHARMA CREDIT PLC (as the "Collateral Agent"), BPCR LIMITED PARTNERSHIP (as successor-in-interest to BioPharma Credit PLC solely in the capacity as a "Lender") and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP (as a "Lender"), each Lender has agreed to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein; and

WHEREAS, Grantor is party to the Guaranty and Security Agreement, dated as of December 20, 2019, in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties (as such agreement may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Guaranty and Security Agreement"), pursuant to which Grantor has executed and delivered the Trademark Security Agreement, dated as of December 20, 2019 (the "Trademark Security Agreement");

WHEREAS, Grantor submitted a Statement of Use with respect to an intent to use Trademark on March 31, 2020 and the USPTO issued a registration certificate with respect thereto on May 19, 2020 as 6,059,005; and

WHEREAS, the parties hereto have agreed to the Trademark Security Agreement pursuant to the terms and conditions hereof to reflect the issuance of 6,059,005;

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Amendment to Schedule 1. Schedule 1 to the Trademark Security Agreement is hereby amended as of the Effective Date by adding to the entry for Ref. 7020.US00 the Registration Number "6,059,005" and the Issued Date "May 19, 2020".

Section 3. Continued Effectiveness. The terms "Trademark Security Agreement," "hereof," "herein" and similar terms as used in the Trademark Security Agreement, and references in the other Loan Documents to the Trademark Security Agreement, shall mean and refer to, from and after the Effective Date, the Trademark Security Agreement as amended by this Amendment. Grantor hereby agrees that all of the covenants and agreements contained in the Trademark Security Agreement and the other Loan Documents are hereby ratified and confirmed in all respects.

Section 4. Further Assurances. Each of Grantor and the Collateral Agent hereby agrees to take any and all further action necessary or proper, as reasonably requested by the Collateral Agent or Lenders, as the case may be, from time to time, to execute, deliver, and acknowledge all such additional documents, agreements, certificates and instruments, and do such further acts, as the Collateral Agent or Lenders may reasonably request to effectuate the terms of this Amendment.

Section 5. Counterparts. This Amendment may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page of this Amendment by facsimile or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.


Section 7. Governing Law. This Amendment and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York without regard to any principle of conflicts of law that could require the application of the law of any other jurisdiction.

*[signature pages follow]*

IN WITNESS WHEREOF, Grantor has caused this Amendment No. 1 to Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

SAREPTA THERAPEUTICS, INC.  
as Grantor

DocuSigned by:  
  
By: \_\_\_\_\_  
34305AA741F3492  
Name: David Tyrone Howton, Jr.  
Title: Executive Vice President, General Counsel,  
and Corporate Secretary

*Signature Page to Amendment No. 1 to Trademark Security Agreement*


**TRADEMARK**  
**REEL: 006994 FRAME: 0883**

ACCEPTED AND AGREED  
as of the date first above written:

BIOFHARMA CREDIT PLC.  
as Collateral Agent

By: Pharmakon Advisors, L.P.,  
its Investment Manager

By: Pharmakon Management I, LLC,  
its General Partner

By   
Name: Pedro Gonzalez de Cosio  
Title: Managing Member

*Signature Page to Amendment No. 1 to Trademark Security Agreement*